Want to see VCNX full AI Analyst Report?
VCNX Stock Chart & Stats
$1.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.31 - $1.50
Previous CloseN/A
Volume2.00
Average Volume (3M)1.46K
Market Cap
$2.01M
Enterprise Value$1.65M
Total Cash (Recent Filing)$1.11M
Total Debt (Recent Filing)$25.00K
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.48
Shares Outstanding2,676,637
10 Day Avg. Volume1,936
30 Day Avg. Volume1,460
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.38
Price to Sales (P/S)1.38
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue2.74
Enterprise Value/Gross Profit2.87
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationThe sharp 2025 revenue increase indicates stronger commercial or partnership-related activity and provides evidence of expanding monetization. If sustained, this growth can improve operating leverage, support development investment, and strengthen the company’s ability to advance its pipeline.
High Gross MarginA very high gross margin suggests that incremental revenue could carry meaningful contribution toward operating costs once the revenue base expands. This creates potential for improved economics over time, although profitability still depends on controlling substantial research and operating expenses.
Proprietary Clinical PlatformThe ActivMAb platform and pepinemab provide a defined scientific foundation rather than an undifferentiated research effort. Multiple evaluated indications across oncology and neuroinflammatory diseases may create several development paths and increase the potential value of successful clinical results.
Bears Say
Persistent Net LossesPersistent net losses show that current revenue is not sufficient to cover operating and development costs. Continued losses can limit internal reinvestment, increase dependence on external financing or partners, and make progress toward sustainable profitability more uncertain over the next several quarters.
Ongoing Cash BurnNegative operating and free cash flow indicate that the business continues consuming cash to fund operations and development. Even though operating burn improved from 2024, ongoing outflows create recurring funding needs and can force financing decisions that dilute flexibility or constrain pipeline investment.
Stressed Balance SheetNegative equity and debt exceeding total assets signal substantial financial strain and reduced balance-sheet flexibility. Higher leverage can increase refinancing and solvency pressure if losses persist, while the weak capital structure may limit the company’s ability to fund programs on favorable terms.
Vaccinex News
VCNX FAQ
What was Vaccinex Inc’s price range in the past 12 months?
Vaccinex Inc lowest stock price was $0.31 and its highest was $1.50 in the past 12 months.
What is Vaccinex Inc’s market cap?
Vaccinex Inc’s market cap is $2.01M.
When is Vaccinex Inc’s upcoming earnings report date?
Vaccinex Inc’s upcoming earnings report date is Nov 16, 2026 which is in 70 days.
How were Vaccinex Inc’s earnings last quarter?
Vaccinex Inc released its earnings results on Mar 18, 2025. The company reported -$1.26 earnings per share for the quarter.
Is Vaccinex Inc overvalued?
According to Wall Street analysts Vaccinex Inc’s price is currently Overvalued.
Does Vaccinex Inc pay dividends?
Vaccinex Inc does not currently pay dividends.
What is Vaccinex Inc’s EPS estimate?
Vaccinex Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaccinex Inc have?
Vaccinex Inc has 2,676,637 shares outstanding.
What happened to Vaccinex Inc’s price movement after its last earnings report?
Vaccinex Inc reported an EPS of -$1.26 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vaccinex Inc?
Currently, no hedge funds are holding shares in VCNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaccinex Inc
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.
Technical Analysis
Theriva Biologics
―
GT Biopharma
―
Revelation Biosciences
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
―
Insiders
―
Mutual Funds
6.13% Other Institutional Investors
93.87% Public Companies and
Individual Investors